A true privilege to close out #GU21 by moderating the RCC rapid abstract session with @SBoorjian to highlight new and innovative RCC data. @ChunLGan@_ShankarSiva@brian_rini, Dr. Jonathon Thouvenin, and Dr. Grant Stewart
So exciting to see such beautiful data about Enfortumab vedotin in mUCC — improved PFS and OS means longer and better lives for patients with this difficult disease! #GU21
90% efficacy is similar to many widely-accepted and used immunizations. Not a virologist or immunologist but so glad to have hope for a vaccine that would protect my wonderful #GUoncology and #palliativecare patients
Beautiful talk by @SuzanneColeMD at #IKCS2020 about real world use of TKI + IO combinations for treating metastatic #kidneycancer, including financial toxicity
Beautiful work by @ShuchiGulati for #IKCS2020 about identifying molecular gene signatures to serve as predictive biomarkers for localized #kidneycancer
Truly a great day to tackle #kidneycancer with multimodal therapy alongside Ivan Pedrosa and Rahul Sheth at #IKCS2020. Especially loved highlighting #PalliativeCare as part of best practices foe all of us!
@tanyawildes Dr. Tawnya Wildes, Hematologist, Geriatric Oncology Specialist, Clinician-Investigator, CEO of her own life, and completely badass, inspiring woman I’m proud to know. Sending love.
The #palliativecare community sprung into action to develop #COVID specific communication tools and toolkits. I certainly would love to see the same in response to killings and mistreatment of black Americans. #HAPC#HPM
Students, faculty & staff, along w/colleagues from @KUHospital and @KUcancercenter, kneeled in solidarity today in recognition of the tragic violence and systemic racism facing the Black community. Now is the time to stand together to address racism. #WhiteCoatsforBlackLives
Many of us routinely push the eligibility criteria for patients with potentially curable disease, but will this extend to those with metastatic disease?
#ASCO20
I wonder if JAVELIN Bladder 100 will change what proportion of patients are considered platinum ineligible to get first line checkpoint inhibitors
@PGrivasMDPhD@tompowles1@urotoday
Practice-changing data for metastatic bladder cancer from JAVELIN 100 demonstrating significantly improved OS with post-chemo Avelumab maintenance #ASCO20
#ASCO20 Very promising ImmuneRx combo Cabozantinib + Atezolizumab in post abi/enza mCRPC #ProstateCancer: Glad to present updated results @ASCO after 12.6 mos of median follow up: 32%ORR, 80%disease control rate. Phase III Contact-2 trial enrolling soon. https://t.co/QcEzpFREwX
Dear Emergency Medicine colleagues,
When this mess is over I vow not to give you a hard time if you want to admit someone with a remote history of cancer to the oncology service. If they need to be admitted to someone that someone can be me. Thank you for being THE front line.
Dear Emergency Medicine colleagues,
When this mess is over, you can all order as many absurd CT scans as you want and I won’t even read the indications before clicking accept.
Keep up the amazing work. You are heroes.
Though the symbol of Valentine’s Day is a heart, it should be a kidney this year! Proud to support these great trials with my fellow investigators! #GU20
So excited to see this great work highlighted — so many patients with prostate cancer ask what else they can do for their cancer control and QOL and I love to see these so-called “lifestyle” interventions brought into conventional oncology care and research.
Kudos to PCF for highlighting importance of diet and exercise during #ProstateCancer treatment at #PCFRetreat19 - Brian Focht from Ohio State shows both components require consistency to reduce ADT side effects. Adherence remains a challenge but patients are interested!
Kudos to PCF for highlighting importance of diet and exercise during #ProstateCancer treatment at #PCFRetreat19 - Brian Focht from Ohio State shows both components require consistency to reduce ADT side effects. Adherence remains a challenge but patients are interested!
@JoshFessel @ctsinclair 1) many pulm folks practice critical care and have a narrow view of palliative care related to inpt palliative care consults for EOL care, 2) so much chronic lung dz is relapsing/remitting, so ideal timing of referral is unclear, 3) doesn’t seem to be a hot funding topic